Product Details
Product Sizes
Size | List Price | Price | Cart |
---|---|---|---|
500,000 | $655.00 | Add to Cart |
These cells are native human MSCs suitable for a variety of basic research studies of self-renewal and differentiation. They are expandable through 12 passages (~ 50 population doublings) and maintain strong growth with slowly decreasing growth rates at later passages. They may be differentiated into chondrocytes, adipocytes, and osteoblasts under appropriate culture conditions and are provided as 500,000 cryopreserved cells. Optimizing your hMSC Cultures: Product is manufactured, tested and validated in an ISO 9001/ISO13485/CLIA certified facility. |
- Product ReviewsWe recently used the hMSCs derived from Umbilical Cord Blood. Their performance was nothing less than excellent. We were highly impressed with their morphology and their doubling rate. In addition the cells respond very well to accutase and maintain their performance after passaging. We highly recommend this cell line. Product Name: Human Mesenchymal Stem Cells (Cat# SC00A1) http://bit.ly/JEmweq MSCGro-Mesenchymal Stem Cell complete, LS (Cat# SC00B1-500) http://bit.ly/1hhZ5m5 Organization: Rodney J. Nash, Ph.D, Georgia State UniversityRodney Nash - Dec 17, 2013 - Rating: 5.0
Leave a review for this product and you could be eligible for a $10 Starbucks gift card.
- Product Publications
Product Publications
If you've used this product in a publication, let us know. Email rose@neuromics.com, with the publication details and you could be eligible for an Amazon gift card.
- Related Products
Related Products
Images
hMSCs (Day 5@37OC) Cultured using our PetakaG3 LOT Training Kit. Courtesy of Dr. Jim Musick, CEO, Vitro Biopharma.
hMSCs (Day 5@37OC) Cultured using our PetakaG3 LOT Training Kit. Courtesy of Dr. Jim Musick, CEO, Vitro Biopharma.
MSCGro vs Competitive Options.
MSCGro vs Competitive Options.
More information found at: http://dx.doi.org/10.1016/j.biomaterials.2016.08.027
More information found at: http://dx.doi.org/10.1016/j.biomaterials.2016.08.027